预测立体定向放疗后早期远隔脑失败及挽救全脑放疗风险评分的外部有效性验证
本研究在247例接受立体定向放疗的脑转移患者中验证Emory风险评分,发现该三级评分不能外部验证,但可区分低危与非低危组早期(≤6个月)远隔脑失败风险;总病灶体积<1.3 cm3、黑色素瘤和多发转移被验证为预测因素,而既往全脑放疗和乳腺癌组织学未保留预后意义。
要点
- Emory三级风险评分外部验证不成立,但低危与非低危组早期远隔脑失败风险可区分。
- 总病灶体积<1.3 cm3、黑色素瘤和多发转移被验证为早期远隔脑失败预测因素。
- 既往全脑放疗和乳腺癌组织学特征未保留预后意义。
核心结论
- Emory三级风险评分外部验证不成立,但模型可区分低危与非低危组早期(≤6个月)远隔脑失败风险。
- 需结合分子信息并在更多当代患者人群中进一步优化该评分系统。
研究设计与样本
- 回顾性外部验证研究,纳入2010至2013年Levine Cancer Institute接受立体定向放疗的247例患者共388个脑转移灶。
- 计算Press(Emory)风险评分并应用于验证队列,采用累积发生率分析风险组。
主要发现
- 低危组早期远隔脑失败风险显著低于高危组(22.6% vs 44%,P=.004)。
- 高危组与中危组早期远隔脑失败风险无差异(41.2% vs 44%,P=.79)。
- 总病灶体积<1.3 cm3(P=.004)、恶性黑色素瘤(P=.007)和多发转移(P<.001)被验证为早期远隔脑失败预测因素。
- 既往全脑放疗和乳腺癌组织学特征未保留预后意义。
- 早期挽救全脑放疗风险分层类似,高危组较低危组风险有升高趋势(P=.09),中危与高危组无差异(P=.53)。
关键数值与推荐
- Emory风险评分包含4个术前因素各计1分:无既往全脑放疗、黑色素瘤或乳腺癌组织学、多发脑转移、脑转移总体积<1.3 cm3。
临床怎么用
- 该评分不宜直接用于三级风险分层,但可尝试区分低危与非低危患者以辅助早期远隔脑失败风险评估。
- 临床决策时应结合分子信息和当代患者特征,并关注评分系统的外部验证结果。
局限性
- 单中心回顾性研究,样本量247例,外部有效性有限。
- 评分系统未纳入分子信息,需进一步优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A scoring system using pretreatment factors was recently published for predicting the risk of early (≤6 months) distant brain failure (DBF) and salvage whole brain radiation therapy (WBRT) after stereotactic radiosurgery (SRS) alone. Four risk factors were identified: (1) lack of prior WBRT; (2) melanoma or breast histologic features; (3) multiple brain metastases; and (4) total volume of brain metastases <1.3 cm3, with each factor assigned 1 point. The purpose of this study was to assess the validity of this scoring system and its appropriateness for clinical use in an independent external patient population. METHODS: We reviewed the records of 247 patients with 388 brain metastases treated with SRS between 2010 at 2013 at Levine Cancer Institute. The Press (Emory) risk score was calculated and applied to the validation cohort population, and subsequent risk groups were analyzed using cumulative incidence. RESULTS: The low-risk (LR) group had a significantly lower risk of early DBF than did the high-risk (HR) group (22.6% vs 44%, P=.004), but there was no difference between the HR and intermediate-risk (IR) groups (41.2% vs 44%, P=.79). Total lesion volume <1.3 cm3 (P=.004), malignant melanoma (P=.007), and multiple metastases (P<.001) were validated as predictors for early DBF. Prior WBRT and breast cancer histologic features did not retain prognostic significance. Risk stratification for risk of early salvage WBRT were similar, with a trend toward an increased risk for HR compared with LR (P=.09) but no difference between IR and HR (P=.53). CONCLUSION: The 3-level Emory risk score was shown to not be externally valid, but the model was able to stratify between 2 levels (LR and not-LR [combined IR and HR]) for early (≤6 months) DBF. These results reinforce the importance of validating predictive models in independent cohorts. Further refinement of this scoring system with molecular information and in additional contemporary patient populations is warranted.
引用
- Press RH, Boselli DM, Symanowski JT, et al. External Validity of a Risk Stratification Score Predicting Early Distant Brain Failure and Salvage Whole Brain Radiation Therapy After Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581405. doi:10.1016/j.ijrobp.2017.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。